Martin H. Schuler, MD, on Gastric and Gastroesophageal Junction Adenocarcinoma: Results of the FAST Study

2016 ESMO Congress
Tweet this page

Martin H.  Schuler, MD, of the University Hospital Essen, discusses findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ disease. (Abstract 614O)

Advertisement

Advertisement



Advertisement